Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Research Services Inc

Neither a doctor nor a teaching hospital

Research payments

$2,993,520

174 payments

Through program year 2025, Clinical Research Services Inc is reported as receiving $2,993,520 in research payments, across 174 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,338,026 40
2024 Research $376,142 17
2023 Research $62,861 8
2022 Research $261,084 31
2021 Research $926,883 58
2020 Research $9,100 11
2019 Research $19,425 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Pfizer Inc. $1,167,326 63 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $708,768 10 payments
  3. AbbVie, Inc. $586,992 21 payments
  4. F. Hoffmann-La Roche AG $342,090 20 payments
  5. Genentech, Inc. $74,695 1 payment
  6. Celgene Corporation $60,411 1 payment
  7. Medtronic Vascular, Inc. $28,525 20 payments
  8. Medtronic, Inc. $24,714 38 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Dosing of TAK-861 in Participants With or Without Hepatic Impairment $569,962 7 payments
  2. A Phase 1 Open-Label Study to Assess the Effect of Hepatic Impairment of Subjects Given CT388 $416,784 21 payments
  3. A Phase 1 Nonrandomized Open Label Single Dose Study to Evaluate the Pharmacokinetics Safety and Tolerability of Pf06700841 in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function $359,890 16 payments
  4. A Phase 1 Openlabel Singledose Parallel Group Study to Evaluate the Pharmacokinetics of Pf06882961 in Participants With Type 2 Diabetes Mellitus With Varying Degrees of Renal Impairment Relative to Participants Without Renal Impairment $310,123 18 payments
  5. A Phase 1 Nonrandomized Openlabel Singledose Parallel Cohort Study to Compare the Pharmacokinetics of Pf06882961 in Adult Participants With Varying Degrees of Hepatic Impairment Relative to Participants Without Hepatic Impairment $278,341 18 payments
  6. A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine $271,103 5 payments
  7. A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function $168,785 9 payments
  8. A Phase 1 Nonrandomized Openlabel Study to Assess the Pharmacokinetics Safety and Tolerability of Pf07321332 Boosted With Ritonavir in Adult Participants With Renal Impairment and in Healthy Participants With Normal Renal Function $150,174 8 payments
  9. A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function $104,089 4 payments
  10. An oral inhibitor of tyrosine kinase 2 (TYK2) that binds to the JH2 pseudokinase domain, resulting in highly selective TYK2 kinase activity compared with the other homologous proteins in the Janus kinase (JAK) family of nonreceptor tyrosine kinases (JAK1, JAK2, and JAK3) $99,798 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record